Share

Morgan Stanley: Could get shots to 75% of vaccine-eligible population by mid-summer

Top-rated biotech analyst Matthew Harrison of Morgan Stanley discusses the pace of the COVID vaccine rollout in the U.S., and concerns about the spread of virus variants.
03:26
Tue, Mar 23 20217:28 AM EDT